Brought to you by 
Allergan acquires NASH player Tobira for $1.695bn
27 May 2021
Executive Summary
In the first of two acquisitions announced on the same day, both focused on the emerging nonalcoholic steatohepatitis (NASH) market, Allergan PLC bought publicly traded Tobira Therapeutics Inc. for $1.695bn, including approximately $534mm up front plus up to $1.2bn in earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Allergan acquires NASH player Tobira for $1.695bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice